News Vicore Pharma Holding AB

Equities

VICO

SE0007577895

Delayed Nasdaq Stockholm Other stock markets 04:57:57 2024-05-14 am EDT			5-day change	1st Jan Change
21.3 ^SEK	+1.19%		+6.48%	+50.56%

May. 07	Vicore Pharma Holding AB Announces Board Appointments	CI
May. 03	Vicore Pharma Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vicore Expands and Strengthens its Board of Directors	02:00am	AQ
Vicore Pharma Holding AB Announces Board Appointments	May. 07	CI
Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)	May. 07	AQ
Interim report January-March 2024	May. 03	AQ
Vicore Pharma Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 03	CI
Vicore to Present at Upcoming April 2024 Investor Conferences	Apr. 15	AQ
Vicore to Present at Upcoming Investor Conferences	Apr. 15	AQ
Vicore to Present at Upcoming Investor Conferences	Apr. 12	AQ
Vicore Pharma Holding AB Announces Maarten Kraan, as Board Member Declined Re-Election	Apr. 04	CI
Notice of annual general meeting of Vicore Pharma Holding AB (publ)	Apr. 04	AQ
Vicore Announces Presentations at the 2024 American Thoracic Society International Conference	Mar. 28	AQ
Vicore publishes the Annual Report for 2023	Mar. 27	AQ
Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis	Mar. 19	AQ
Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis	Mar. 19	CI
Year-end report 2023	Feb. 28	AQ
Vicore Pharma Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Vicore Pharma Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Vicore to Present at Upcoming Investor Conferences	Feb. 27	AQ
Vicore Pharma Signs Licensing Deal for Idiopathic Pulmonary Fibrosis Drug Candidate	Feb. 09	MT
Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan	Feb. 09	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Vicore Pharma Holding AB

Equities

VICO

SE0007577895

Summary

Filters